chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Wed, 12/17 - 5pm vaccine into triceps left arm. Thu, 12/18 - In the afternoon the arm felt sore and it hurt when I used my left arm. Fri, 12/19 - Soreness continued, but now also strong itch and 5inch long oval red skin, very difficult not to scratch. Sat, 12/20 - Strong itching continued, soreness however slightly less, slowly disappearing over the day. Sun, 12/21 - Soreness gone, former red spot normal color again and little itching, but now a 1 inch wide border around the former spot is red and itching, towards elbow; injection spot still red, itch also on rear of arm/shoulder rotator cuff area. Mon, 12/22 - Slight sensitivity when touching the triceps area, but no other issues.
VASOVAGAL SYNCOPE- PATIENT FELT FAINT, AND LIGHT HEADED BUT DID NOT PASS OUT.  PATIENT FELT WARM FOLLOWED BY A PERIOD OF COLD CHILLS.  PATIENT STATED WAS SIMILAR TO A PREVIOUS EPISODE AND IDENTIFIED A VASAVAGAL REACTION IN THE PAST.
2 weeks after the vaccine, I was having brain fogginess. I was feeling heaviness in my brain. I felt really full in my head, like I was about to have a stroke. I felt like it was no oxygen going to brain, I cannot focus. I cannot focus and pay attention. I have a slow thinking, confusion, unable to concentrate. I had flunked my exam because I could not think or focus to take my test. I want to ask my doctor to give me an MRI, or CT of my Brain. My ability to think and concentrate is altered. I have a difficulty remembering things now. I feel like a slow thinker. I was doing okay and writing programs and now I cannot study, it's so difficult to remember things. I feel altered in my personality as well. I have to sleep to rid of the heaviness, I have to sleep and wake up with the fullness in my head. I wake up not remembering why I am moving or what I was going to do. No my vision is also worse, I have changed glasses twice and I cannot see at night.
Patient received Moderna Spikevax 2023-2024 Formula on 10/30/23.  Our team was given some training before administering the vaccine, but we did not know that the vaccine needed a thaw time and Medical Assistant was applying heat to the frozen vaccine with her hands for up to 15-20 min until it turned into liquid. Patient has been called and stated no symptoms signs or any effects after receiving the vaccine.
patient received 3rd dose on 19-Aug-2021; She has been "so sick"; a horrible metallic taste in her mouth; she "felt like she had the flu"; red rash; very hot rash; itchiness/itching; it "has been a nightmare."; fever up to 103; headache; muscle pains/arm soreness; This spontaneous case was reported by a consumer and describes the occurrence of INCORRECT DOSE ADMINISTERED (patient received 3rd dose on 19-Aug-2021), ILLNESS (She has been "so sick"), DYSGEUSIA (a horrible metallic taste in her mouth), INFLUENZA LIKE ILLNESS (she "felt like she had the flu") and RASH ERYTHEMATOUS (red rash) in a 65-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 939893, 011L20A and 031L20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     The patient's past medical history included Immunocompromised (compromised immune system with leukemia). Concurrent medical conditions included Leukemia.   On 23-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 20-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 19-Aug-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. In August 2021, the patient experienced ILLNESS (She has been "so sick"), DYSGEUSIA (a horrible metallic taste in her mouth), INFLUENZA LIKE ILLNESS (she "felt like she had the flu"), RASH ERYTHEMATOUS (red rash), SKIN WARM (very hot rash), PRURITUS (itchiness/itching), NIGHTMARE (it "has been a nightmare."), PYREXIA (fever up to 103), HEADACHE (headache) and MYALGIA (muscle pains/arm soreness). On 19-Aug-2021, the patient experienced INCORRECT DOSE ADMINISTERED (patient received 3rd dose on 19-Aug-2021). The patient was treated with PARACETAMOL (TYLENOL) for Fever, at an unspecified dose and frequency and IBUPROFEN (ADVIL [IBUPROFEN]) for Fever, at an unspecified dose and frequency. In August 2021, PRURITUS (itchiness/itching) had resolved. At the time of the report, INCORRECT DOSE ADMINISTERED (patient received 3rd dose on 19-Aug-2021), ILLNESS (She has been "so sick"), DYSGEUSIA (a horrible metallic taste in her mouth), INFLUENZA LIKE ILLNESS (she "felt like she had the flu"), RASH ERYTHEMATOUS (red rash), SKIN WARM (very hot rash), NIGHTMARE (it "has been a nightmare."), HEADACHE (headache) and MYALGIA (muscle pains/arm soreness) outcome was unknown and PYREXIA (fever up to 103) was resolving.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): In 2021, Body temperature: bring it down for 4 hours (Low) which would bring it down for 4 hours before raising again. In August 2021, Body temperature: up to 103 (High) up to 103.         No concomitant products was provided by the reporter. The patient had been using ice on her arm as a self-treatment method and her itching symptom went away.   This case was linked to MOD-2021-294276 (Patient Link).
Hand cramps; Persistent, muscle weakness in injection arm; Numbness in injection arm; Occasional, heart palpatations; Severe, persistent leg and muscle pain in left leg( side of injection).; This spontaneous case was reported by a physician and describes the occurrence of MUSCLE SPASMS (Hand cramps), MUSCULAR WEAKNESS (Persistent, muscle weakness in injection arm), HYPOAESTHESIA (Numbness in injection arm), PALPITATIONS (Occasional, heart palpatations) and MYALGIA (Severe, persistent leg and muscle pain in left leg( side of injection).) in a 71-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Concurrent medical conditions included Hypertension and Diabetes.   On 01-Apr-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form once. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 14-Apr-2021,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced MYALGIA (Severe, persistent leg and muscle pain in left leg( side of injection).). On an unknown date, the patient experienced MUSCLE SPASMS (Hand cramps), MUSCULAR WEAKNESS (Persistent, muscle weakness in injection arm), HYPOAESTHESIA (Numbness in injection arm) and PALPITATIONS (Occasional, heart palpatations). At the time of the report, MUSCLE SPASMS (Hand cramps), MUSCULAR WEAKNESS (Persistent, muscle weakness in injection arm), HYPOAESTHESIA (Numbness in injection arm), PALPITATIONS (Occasional, heart palpatations) and MYALGIA (Severe, persistent leg and muscle pain in left leg( side of injection).) had not resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No treatment product was reported  Concomitant product included for the maintenance for Diabetes and Hypertension
Pt developed several "spots" around neck and trunk and became flushed with a temperature of 101.5F, on the afternoon of 3/11/01. The spots darkened and spread over the next 2 days to her entire body with the densest rash on the neck and chest. Pt had a mild temperature of 101F-102F over those 2 days. The rash gradually lightened over the next 5 days.
Redness, swelling, pruritis and rash to R upper extremity (site of vaccination) persisting now 4 days.  Treatment received from local Urgent Care for presumed cellulitis (oral antibx) then further hospitalization on 8/27-28 for unresolved and worsening presumed cellulitis (IV antibx x 1 day). No fevers or chills noted or evidence of cellulitis upon hospital Infectious Disease consultation.
This spontaneous case was reported by a patient and describes the occurrence of GAIT DISTURBANCE (Could barely walk), LOSS OF PERSONAL INDEPENDENCE IN DAILY ACTIVITIES (Could not even hold a coffee cup) and ARTHRALGIA (joint pain/inflammation) in a 63-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 prophylaxis.    Co-suspect product included non-company product TOFACITINIB CITRATE (XELJANZ XR) for an unknown indication.    No Medical History information was reported.   In March 2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. In April 2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. In November 2022, the patient started TOFACITINIB CITRATE (XELJANZ XR) (unknown route) 11 milligram. In 2021, the patient experienced GAIT DISTURBANCE (Could barely walk), LOSS OF PERSONAL INDEPENDENCE IN DAILY ACTIVITIES (Could not even hold a coffee cup) and ARTHRALGIA (joint pain/inflammation). The patient was treated with VITAMIN D NOS at a dose of 1500, wk; IBUPROFEN (ADVIL [IBUPROFEN]) in 2021 at an unspecified dose and frequency; METHOTREXATE at a dose of 2.5 milligram once a week; FOLIC ACID at a dose of for 4-6 weeks; PREDNISONE at a dose of 40 milligram every two weeks; PREDNISONE at a dose of 30 milligram every two weeks; PREDNISONE at a dose of 20 milligram every two weeks; PREDNISONE at a dose of 50 milligram every two weeks and PREDNISONE at a dose of 10 milligram every two weeks. At the time of the report, GAIT DISTURBANCE (Could barely walk), LOSS OF PERSONAL INDEPENDENCE IN DAILY ACTIVITIES (Could not even hold a coffee cup) and ARTHRALGIA (joint pain/inflammation) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Blood test: Normal.         No concomitant medications were reported.
Patient c/o feeling dizzy and lilting to the left.  Unsteady on his feet.  B/P 162/87, HR 92 SPO2 100%, starting feeling nasal passages becoming stuffy, used EpiPen at 1310 and repeated at 1315 when he c/o heaviness in chest.  HR increased to 105, TEAM alert CALLED and patient taken to the emergency room.
A large red swollen and itchy bump appeared on my arm about a week after I received the shot. It is further down my arm than the injection site but aligns with pictures and reports of "Covid arm" I've researched and heard about from friends.
This spontaneous report as received from a pharmacist refers to a 67 year old female patient. On 01-MAY-2013 the patient was vaccinated with ZOStAVAX lot # J000436, exp. 10-APR-2014, 0.65 ml, subcutaneous for prophylaxis. The patient experienced "bad swelling, warm to touch and redness" of upper arm after the patient received ZOSTAVAX, at the pharmacy. The patient sought medical attention by contacting physician and was treated iwth BENADRYL and ice topically. At the time of reporting, the outcome was unknown. The pharmacist explained adverse event was reported to VAERS. Pharmacist requested lot check for ZOSTAVAX (lot # J000436, exp. 10-APR-2014). This is one of the reports from the same reporter (SR#1-7171986880, SR#1-7176426810 and 1-7176426358 (1305USA009032)). Additional information has been requested.
Day after vaccine felt numbness in right hand and heaviness in arm. Feels it has improved some. Also weakness in right hand. No local pain, heat, redness or swelling.
Patient suddenly became tired and lethargic and refused to eat then she began vomiting over and over again. She dehydrated very quickly. Ran only a low grade fever. Complained constantly that her hands were tingly and her fingers were completely numb. She may Require IV fluids since she can not keep any liquids down. She has not been around anyone that was ill so I looked online and found that TONS of people have become ill from these vaccines, especially the live vaccine given in the nose which is what was given to patient. People are complaining of the exact same symptoms anywhere from one day to a month after receiving the H1N1 vaccine.
fatigue; This is a spontaneous report received from a contactable reporter(s) (Physician) from medical information team. The reporter is the patient.  A female patient received bnt162b2 (BNT162B2) (Batch/Lot number: unknown) as dose 1, single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: FATIGUE (non-serious), outcome "unknown", described as "fatigue".  Additional Information: I had fatigue after first and second shot.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Received telephone call from pt's mother at approx. 5:45pm. She stated that the child broke out in a rash about an hour ago. Pt's mom also stated that she did try a half teaspoon of Benadryl. Pt did not have any fever or respiratory difficulties. I advised mom she should take pt to flu clinician. On 03/27/2002 spoke with pt's mom. Rash was on face, and trunk. Mom states rash was almost gone before seen clinician.
Pediatric dose administered to an adult patient; Pediatric dose administered to an adult patient; This case was reported by a nurse via call center representative and described the occurrence of underdose in a 29-year-old female patient who received HBV (Engerix B pediatric) (batch number D294, expiry date 19th April 2024) for prophylaxis.   On 27th October 2022, the patient received Engerix B pediatric. On 27th October 2022, unknown after receiving Engerix B pediatric, the patient experienced underdose and adult use of a child product. On an unknown date, the outcome of the underdose and adult use of a child product were unknown.   Additional Information: GSK receipt date: 27-Oct-2022 Reporter's comment: The reporter did not consent to follow-up. Additional supportive information: The patient received a pediatric dose of Engerix-B, which led to underdose and adult use of a child product.
Red hot swollen upper arm 8 x 10 cm. Very red center 4.5 x 5cm gradually resolved.
Severe chest pain, unable to sleep through the night, had to sit up the whole night which helped some, but not much. Excruciating upper chest pain. Lasted about 15 hours. Took acetaminophen.
Pt reported rash (dark spots on thorax, abdomen, arms, and shoulder, beginning 10-12 hours after receiving Influenza vaccine at work in hospital on 10/20/2006.
This spontaneous report as received from a other health professional refers to a 17 year old male patient with osteogenesis imperfecta, pathological fracture and food allergy. On 22-JUN-2017 the patient was vaccinated with GARDASIL 9 lot # N004798 dose 1, 1 DF for prophylaxis. On 2017 the patient experienced ear disorder. The outcome of ear disorder was reported as not recovered/not resolved.
Swollen area of (L) upper arm, 10cm x 9cm. Firm & warm to touch. Pt c/o soreness & inability to lift her (L) arm. Injection site is intact with no swelling, redness or drainage.
Fever 102.4, Chills, Headache, Body ache, Nausea
pt received HD flu and is not in the recommended age range to receive this vaccine. pt notified and provider notified.
After receiving the vaccination in the evening, spouse has Altemizer disease he became non communitive, lethargic, physical depressed, lack of energy and lack of ability to interactive. Depressed or declined in interaction, action.  No treatment and the next day he was fine and was better than usual bounce back to his usual self.
Weak; Fever/She had fever for a day in half; Chills; Patient missed her 2nd dose of the vaccine; This spontaneous case was reported by a consumer and describes the occurrence of ASTHENIA (Weak), PYREXIA (Fever/She had fever for a day in half), CHILLS (Chills) and PRODUCT DOSE OMISSION ISSUE (Patient missed her 2nd dose of the vaccine) in a 20-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 039B21A) for COVID-19 vaccination.     No Medical History information was reported.    On 15-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced ASTHENIA (Weak), PYREXIA (Fever/She had fever for a day in half), CHILLS (Chills) and PRODUCT DOSE OMISSION ISSUE (Patient missed her 2nd dose of the vaccine). At the time of the report, ASTHENIA (Weak) and CHILLS (Chills) outcome was unknown and PYREXIA (Fever/She had fever for a day in half) and PRODUCT DOSE OMISSION ISSUE (Patient missed her 2nd dose of the vaccine) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       The patient was not taking any concomitant medications. No treatment details were reported.  Patient missed her second dose as her vaccination location was closed. Her HCP was not aware that she did not get her second dose.
Vaccines went into 2-8 C thaw state on or about 24-Dec-2021 and was administered on 18-Mar-2022; Patient received vaccine 30-days Expiry date; This spontaneous case was reported by an emergency medical technician and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Patient received vaccine 30-days Expiry date) and PRODUCT STORAGE ERROR (Vaccines went into 2-8 C thaw state on or about 24-Dec-2021 and was administered on 18-Mar-2022) in a 41-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 066H21A) for COVID-19 vaccination.     No Medical History information was reported.    On 18-Mar-2022 at 2:17 PM, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .25 milliliter. On 18-Mar-2022 at 2:17 PM, the patient experienced EXPIRED PRODUCT ADMINISTERED (Patient received vaccine 30-days Expiry date). On an unknown date, the patient experienced PRODUCT STORAGE ERROR (Vaccines went into 2-8 C thaw state on or about 24-Dec-2021 and was administered on 18-Mar-2022). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Patient received vaccine 30-days Expiry date) and PRODUCT STORAGE ERROR (Vaccines went into 2-8 C thaw state on or about 24-Dec-2021 and was administered on 18-Mar-2022) outcome was unknown. For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   The patient was given booster dose on 18-MAr-2022, 14:17:58. Prescriptions, over the counter medications, dietary supplements or herbal medicines being taken at the time of vaccination and or at the time of adverse event was unknown. Treatment and concomitant information was not provided.   This case was linked to MOD-2022-542869 (Patient Link).
Given COVID19 vaccine out of approved age range; patient is only 16 and approved age is 18 and above.
Covid rash, sick with headaches, fever horrible chills ,back pain ,glands swollen. Everything except for rash within 10 hrs period of vacation.  Rash about a day later
arm was extremely red; it swelled; very itchy; has those welts; the size is now much bigger like her fist size; it's very large; black and blue mark; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE DISCOLOURATION (black and blue mark), ERYTHEMA (arm was extremely red), PERIPHERAL SWELLING (it swelled), PRURITUS (very itchy) and URTICARIA (has those welts) in a 74-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 013M20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    On 04-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 09-Feb-2021, the patient experienced VACCINATION SITE DISCOLOURATION (black and blue mark). On 11-Feb-2021, the patient experienced ERYTHEMA (arm was extremely red), PERIPHERAL SWELLING (it swelled), PRURITUS (very itchy), URTICARIA (has those welts), SWELLING (the size is now much bigger like her fist size) and ERYTHEMA (it's very large). At the time of the report, VACCINATION SITE DISCOLOURATION (black and blue mark), ERYTHEMA (arm was extremely red), PERIPHERAL SWELLING (it swelled), PRURITUS (very itchy), URTICARIA (has those welts), SWELLING (the size is now much bigger like her fist size) and ERYTHEMA (it's very large) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       The patient was born in the year 1946 Treatment medications included cortisone cream. No relevant concomitant medications were reported.   Most recent FOLLOW-UP information incorporated above includes: On 13-Jul-2021: Follow information received on 13 Jul 2021 and reporter information was updated.
suspected vaccination failure; had 2 flu shots and the flu both times; This case was reported by a consumer via interactive digital media and described the occurrence of suspected vaccination failure'in a patient who received Flu Seasonal QIV Dresden (Influenza vaccine Quadrivalent unspecified season) for prophylaxis.   On an unknown date, the patient received Influenza vaccine Quadrivalent unspecified season. On an unknown date, unknown after receiving Influenza vaccine Quadrivalent unspecified season, the patient experienced vaccination failure (serious criteria GSK medically significant) and influenza. On an unknown date, the outcome of the vaccination failure and influenza were unknown.   It was unknown if the reporter considered the vaccination failure and influenza to be related to Influenza vaccine Quadrivalent unspecified season.  Additional details were provided as follows:   The age at vaccination was not reported. The patient had flu shot and the had flu, he or she was staying away from this shot. This case was considered as suspected vaccination failure as details regarding completion of primary vaccination schedule, time to onset, laboratory confirmation test were unknown at the time of reporting. This case was linked with case US2020AMR236391, reported by the same reporter for the same patient.; Sender's Comments:  US-GLAXOSMITHKLINE-US2020AMR236391:same reporter
Well demarcated area of erythema, swelling, tenderness and warmth in left upper arm that developed 72 hours after vaccine administration. Hydrocortisone 1% cream.
soreness at site; swelling at site; fatigue (slept for 12 hours next night); abdominal pain; This is a spontaneous report from a contactable consumer. This 79-year-old female consumer reported for herself that she received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, lot number: unknown) intramuscular at single dose for COVID-19 immunisation on 20Jan2021, at 05:30 PM. The patient did not receive other vaccine same date. Relevant history included apnea, depression, high blood pressure, reflux, 2 strokes, restless legs and allergies with Clarithromycin, compazine, Hydrocodone; kiwi, peppers. The patient was not pregnant. The patient was not diagnosed with COVID prior vaccination. The patient did not have COVID test post vaccination. Relevant concomitant medications in two weeks includes amlodipine, atorvastatin, duloxetine, plus more. The patient did not receive other vaccine in four weeks of vaccination. The patient experienced soreness at site, swelling at site, fatigue (slept for 12 hours next night); abdominal pain (may be unrelated) since 20Jan2021 at 08:00 PM. The events reported as non-serious. Treatment therapy included Acetaminophen. Outcome of events was resolved.   Information about lot/batch number has been requested.
Patient received Janssen vaccine and passed out/threw up after receiving vaccine. She told us ahead of time that she occasionally passes out with blood draws, but never had any issue after a vaccine. About 3-5 minutes after the vaccine, the patient turned very pale and passed out in her chair. She did not fall on the floor but slumped to the side as we held her in place. After she came to she threw up. We had called 911 because it took her a while to wake up. EMS arrived and she was already feeling much better. They took her blood pressure and cleared her. Patient waited another 30 minutes after they left to make sure she was still feeling okay.
pt recv vax & exp joint pain;pt dx w/ankylosing spondylitis;